Hospital de Amor, Barretos

Barretos 14784400

3 studies enrolling now · 8 studies all time

What they study most

Gastroesophageal Junction Adenocarcinoma, Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen, Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation, Marginal Zone Lymphoma, Metastatic Gastric Adenocarcinoma, Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC), One-Lung Ventilation, Relapsed/Refractory Follicular Lymphoma, Septic Shock, Vasodilatory Shock

Studies at this site

• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — Recruiting now
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer — Running, not enrolling
• Protective Ventilation With High Versus Low PEEP During One-lung Ventilation for Thoracic Surgery — Completed
• Heparin Anticoagulation in Septic Shock — Stopped early